Intensity Therapeutics said today that the 1st patient was treated in a Phase I/II trial of its intratumorally-administered cancer therapy, INT230-6.
The company’s plans to evaluate the safety of its cancer-killing agent in patients with tumors that are treated at the surface of the skin, including breast cancer and melanoma. Intensity Therapeutics also plans to study INT230-6 in patients with deep tumors.
Get the full story at our sister site, Drug Delivery Business News.
The post Intensity Therapeutics begins human testing of intratumoral cancer drug appeared first on MassDevice.